






































An improved understanding of B cell lineage acute 
lymphoblastic leukaemia (B-ALL) pathophysiology has 
been gained in the process of identification of the 
genetic abnormalities consistently present in B-cell 
blasts [1-3]. A rather limited variety of gene fusions 
created by chromosomal translocations are involved in 
the genesis of B-ALL: basically TEL-AML1,  MLL 
rearrangements,  BCR-ABL and E2A-PBX1 [2, 4]. 
However, the frequency of genetically defined 
leukaemia subtypes differs between children and adults: 
for example, TEL-AML
+ leukaemias are almost 
exclusively present in children (22% of ALLs vs 2% in 
the adults) while BCR-ABL
+ ALLs are much more 
frequent in adults (25% vs. 3% in children) [2, 4, 5]. 
BCR-ABL
+  (and, in most of the  cases,  specifically the  
 
 





































BCR-ABLp190 protein form) represents the most 
frequent cytogenetic abnormality (25–30% of cases) in 
adults and defines the B-ALL subset with the most 
unfavorable prognosis [6]. Increased age has a negative 
impact on human B-ALL survival and directly 
correlates with increased incidence, malignancy, and 
treatment resistance [3]. However, little is known about 
age-related mechanisms that impact B-ALL malig-
nancy. There are many evidences indicating that aging 
has a clear impact both in the numbers and in the 
functionality of stem cells [7-12] and B lymphoid 
progenitors [13-15]. It has been described that BCR-
ABLp190
+ leukaemias have to originate from early 
progenitors/stem cells, given the fact that the oncogene 
cannot by itself endow the target cell with stem cell 
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purified subpopulations into immunocompromised 
mice [4, 17, 18]. Therefore, any impact that age 
might have on the target cell-of-origin population 
may reflect in the characteristics of the leukemic 
disease. 
 
A major obstacle to elucidate the contribution of age to 
the development and evolution of leukaemias is the lack 
of appropriate mouse models where precise control of 
the timing of oncogene expression is possible. Here we 
present proof-of-principle experiments showing how a 
conditional transgenic mouse model of BCR-ABLp190-
driven B-ALL offers the opportunity to evaluate the 





































RESULTS AND DISCUSSION 
 
Survival of BCR-ABL
+ ALL cells is cell-autonomous 
and independent of the host’s age 
 
To determine the impact of host age on the survival of 
BCR-ABL
+ leukemic cells, 1 x 10
5 cells of a 
characterized B-ALL cell line Ba/F3-p190 [19] were 
injected intravenously into syngenic host mice of 4 (n = 
16) or 20 (n = 11) months of age. Injected mice started 
to die due to leukemic infiltration (data not shown) 
around 20 days post-injection. Kaplan-Meier survival 
plot demonstrates that there is no difference in survival 
between young or old recipient mice (log rank test P = 
0.9011) (Figure 1). These results indicate that host age 
does not influence BCR-ABL












































line  Ba/F3‐p190  (REF)  were  IV  injected  into
syngeneic host mice aged 4 months (n = 16) or 20
months  (n  =  11).  Kaplan‐Meier  survival  plot
demonstrates  no  difference  in  survival  (log  rank
test P = 0.9011).  
Figure  2.  Transformed  hematopoietic  pro‐
genitor/stem cells express comparable levels
of  exogenous  BCR‐ABL.  Expression  of  BCR‐ABL
was  measure  by  real‐time  PCR  in  BM  cells  of
CombitTA‐p190  mice  at  the  age  of  4  months,  12
months,  and  20  months.  Doxycycline  was  given  at
4mg/mL for 4 months, 12 months, and 20 months.
BCR‐ABL  expression  was  measured  in  CombitTA‐
p190 mice under doxycycline treatment (+) and mice


















































Age-dependent malignancy of transformed 
hematopoietic progenitor cells in vivo 
 
As mentioned, BCR-ABLp190
+ A L L s  h a v e  b e e n  
identified as being originated in cells with the 
characteristics of a stem cell, and there are many 
evidences indicating that aging affects both the numbers 
and the functionality of stem cells and B lymphoid 
progenitors. Therefore, to investigate if the age of the 














































we have taken advantage of the doxycline-controlled 
transgenic CombitTA-BCR-ABLp190 mouse line [20] 
to induce the expression of the leukaemia-triggering 
oncogene in mice of different ages. The CombitTA-
BCR-ABL-p190 mice expressing the BCR-ABL
p190 
chimeric gene product have previously been described 
to consistently show the B-ALL pathologic phenotype 
with which this oncogene is associated in humans [20]. 
In the present work, BCR-ABLp190 expression was 








expressed  B‐cell  and  myeloid  markers  indicated  by  the  presence  of  Mac
+B220
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removing the doxycycline from the drinking water. All 
mice demonstrated equivalent levels of exogenous 
BCR-ABL expression, thus precluding any effect from 
transgene expression changes with age (Figure 2).  
 
In order to test the age-dependent malignancy of 
transformed hematopoietic progenitor cells in vivo in 
the least biased manner possible, and to exclude any 
potential non cell-autonomous, age-related, effect on the 
disease evolution, bone marrow cells were purified from 
CombitTA-BCR-ABLp190 sacrificed mice in which 
BCR-ABL expression had been kept repressed all life. 
Then, cells from donors sacrificed at either 4-, 12- or 
20-months were injected intravenously into syngenic 
host mice of 4 months of age. This transplantation into a 
non doxicyclin-treated recipient lead to transgene 
derepression and expression of the oncogene in a 
simultaneous manner. 100% of the injected mice 
developed B-ALL with all the phenotypic 
characteristics previously described for the CombitTA-
BCR-ABLp190 mice [20], namely the presence in the 
peripheral blood of organ-infiltrating blast cells co-
expressing B-cell and myeloid markers (Figure 3). 
However, B-ALL derived from 12- and 20-month 
transformed HSCs could be distinguished by two 
distinct but interrelated relevant features: first, 20-
month-ALLs presented increased cellularity of B220, 
Mac1 co-expressing blasts (Figure 3B-C). Second, and 
most importantly, animals with B-ALL derived from 4-
month-old donors survived nearly twice as long as those 
with B-ALL from 12- and 20-month-old donors (88 
versus 50.5 and 33 days, respectively; log rank P < 
0.0001 and 0.0001, respectively; Figure 3A). These 
findings therefore prove that the malignancy of B-ALL 
increases with the age of the leukemic-cell-of-origin 
(i.e., with the age of the normal progenitors from which 
the disease arises). Leukaemias originating from older 
progenitors present a more aggressive phenotype, and 
have a much faster evolution, than leukaemias 
initiating in young progenitors. Our results also show 
that, to a great extent, disease evolution is 
programmed from the beginning, since the starting cell 
determines the aggressiveness of the phenotype, and 
also that the decline of the immune response with age 
is not responsible for the increased development or 
aggressiveness of the tumours in the elderly. In 
agreement with these observations it has been recently 
shown, using a retroviral transduction system, that 
aged B-cell progenitors present a reduced fitness due 
to impaired signaling machinery and that this, since 
the oncogene covers in part the need for kinase 
signaling, promotes the positive selection for BCR-
ABL
+ cells [21]. 
In summary, our study of B-ALL provides the first in 
vivo experimental evidence, using a conditional 
transgenic mouse model, showing that an increase in the 
age at which transformation occurs has a direct impact 
in the malignant potential of cancer cells. This is in 
agreement with clinical observations showing that age-
related cell intrinsic factors may play a leading role in 
the impact of age on B-ALL malignancy [3]. Also, 
these findings further support the clinical relevance of 
this model and its uselfulness for future studies to 
determine how specific oncogenic mechanisms affect 
age-related malignancy, and to determine how age-
related cell-extrinsic host mechanisms such as immune 




Cell culture.  Cell lines used include Ba/F3 cells 
expressing the human protein BCR−ABL
p190  (Ba/F3-
p190) [19]. Cells were maintained in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 
10% fetal calf serum (FCS).  
 
Mice and transplantation experiments. The CombitTA-
BCR-ABL
p190 mice have been previously described [20]. 
In order to investigate the impact of age of the target 
cells in B-ALL malignancy, bone marrow 
transplantation experiments were performed. BM cells 
were isolated and highly purified from either 4-, 12- and 
20-month old CombitTA-p190 mice that had been kept 
on doxicycline water for all their life. Marrow cells 
were flushed from the femurs with a syringe containing 
2 mL PBS-1% FBS. In each cohort these BM cells were 
injected into the tail vein of the irradiated recipient 
syngenic mice (4 Gy) at 1 x 106 cells per mouse. All 
recipients were maintained in microisolator cages on 
sterilized food and acidified sterile water. Diseased 
recipient mice were sacrificed and assessed for B-cell 
leukaemia development. All experiments were done 
according to the relevant regulatory standards.  
 
Flow cytometry.  Nucleated cells were obtained from 
total mouse bone marrow (flushing from the long 
bones), peripheral blood, thymus, liver or spleen. In 
order to prepare cells for flow cytometry, contaminating 
red blood cells were lysed with RCLB lysis buffer and 
the remaining cells were then washed in PBS with 2% 
FCS. After staining, all cells were washed once in PBS 
with 2% FCS containing 2 mg/mL propidium iodide 
(PI) to allow dead cells to be excluded from both 
analyses and sorting procedures. Monoclonal antibodies 
were obtained from Pharmingen. The samples and the 
data were analyzed in a FACSCalibur using the 
CellQuest software (Becton Dickinson). Specific 
fluorescence of FITC and PE excited at 488 nm (0.4 W) 
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forward and orthogonal light scattering properties of 
mouse cells were used to establish gates. Unspecific 
antibody binding was suppressed by preincubation of 
cells with CD16/CD32 Fc-block solution (BD 
Pharmingen). For each analysis, a total of at least 5.000 
viable (PI-) cells were assessed. 
 
Real-time PCR quantification. To analyze expression of 
CombitTA-p190 in Sca1
+Lin
- cells, total RNA was 
prepared using the Trizol Reagent (Gibco-BRL). 
Reverse transcription (with random hexamer primers) 
was performed as described [22]. Real-time quantitative 
PCR was carried out for the quantitation of CombitTA-
p190. Fluorogenic PCRs were set up in a reaction 
volume of 50 ml using the TaqMan PCR Core Reagent 
kit (PE Biosystems). cDNA amplifications were carried 
out using the same primers in a 96-well reaction plate 
format in a PE Applied Biosystems 5700 Sequence 
Detector. Thermal cycling was initiated with a first 
denaturation step of 10 min at 95
oC. The subsequent 
thermal profile was 40 cycles of 95
oC for 15 s, 56
oC for 
30 s, 72
oC for 1 min. Multiple negative water blanks 
were tested and a calibration curve determined in 
parallel with each analysis. The abl endogenous control 
(PE Biosystem) was included to relate CombitTA-p190 
to total cDNA in each sample. The sequences of the 
specific primers and probe were as follow: BCR-
ABL
p190, sense primer 5’-CCGCAAGACCGGGCAGAT 
-3’,  antisense primer 5’-CAGATGCTACTGGCCGCT 
GA-3’ and probe 5´-TGGCCCAACGATGGCGAGGG-
3’; c-Abl, sense primer 5’-CACTCTCAGCATCACTA 
AAGGTGAA-3’, antisense primer 5’-CGTTTGGGCT 
TCACACCATT-3’,  and probe 5’-CCGGGTCTTGGG 
TTATAATCACAATG-3’.  
 
Statistical analysis. Statistical analysis of differences in 
Kaplan-Meier survival plots was performed using the 
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